Zobrazeno 1 - 10
of 41
pro vyhledávání: '"Catriona Byrne"'
Autor:
Jesús F. San-Miguel, Maria-Asunción Echeveste Gutierrez, Ivan Špicka, María-Victoria Mateos, Kevin Song, Michael D. Craig, Joan Bladé, Roman Hájek, Christine Chen, Alessandra Di Bacco, Jose Estevam, Neeraj Gupta, Catriona Byrne, Vickie Lu, Helgi van de Velde, Sagar Lonial
Publikováno v:
Haematologica, Vol 103, Iss 9 (2018)
This phase I/II dose-escalation study investigated the all-oral ixazomib-melphalan-prednisone regimen, followed by single-agent ixazomib maintenance, in elderly, transplant-ineligible patients with newly diagnosed multiple myeloma. Primary phase I ob
Externí odkaz:
https://doaj.org/article/eb5cdd404bbb4be487d69252d260e291
Autor:
Fredrik H Schjesvold, Meletios-Athanasios Dimopoulos, Sosana Delimpasi, Pawel Robak, Daniel Coriu, Wojciech Legiec, Luděk Pour, Ivan Špička, Tamas Masszi, Vadim Doronin, Jiri Minarik, Galina Salogub, Yulia Alekseeva, Antonio Lazzaro, Vladimir Maisnar, Gábor Mikala, Laura Rosiñol, Anna Marina Liberati, Argiris Symeonidis, Victoria Moody, Marcus Thuresson, Catriona Byrne, Johan Harmenberg, Nicolaas A Bakker, Roman Hájek, Maria-Victoria Mateos, Paul G Richardson, Pieter Sonneveld, Fredrik Schjesvold, Anna Nikolayeva, Waldemar Tomczak, Ludek Pour, Ivan Spicka, Gabor Mikala, Laura Rosinol, Tatiana Konstantinova, Anargyros Symeonidis, Moshe Gatt, Arpad Illes, Haifaa Abdulhaq, Moez Dungarwalla, Sebastian Grosicki, Roman Hajek, Xavier Leleu, Alexander Myasnikov, Paul G. Richardson, Irit Avivi, Dries Deeren, Mercedes Gironella, Miguel Teodoro Hernandez-Garcia, Joaquin Martinez Lopez, Muriel Newinger-Porte, Paz Ribas, Olga Samoilova, Eric Voog, Mario Arnao-Herraiz, Estrella Carrillo-Cruz, Paolo Corradini, Jyothi Dodlapati, Miquel Granell Gorrochategui, Shang-Yi Huang, Matthew Jenner, Lionel Karlin, Jin Seok Kim, Agnieszka Kopacz, Nadezhda Medvedeva, Chang-Ki Min, Roberto Mina, Katrin Palk, Ho-Jin Shin, Sang Kyun Sohn, Jason Tache, Achilles Anagnostopoulos, Jose-Maria Arguiñano, Michele Cavo, Joanne Filicko, Margaret Garnes, Janusz Halka, Kathrin Herzog-Tzarfati, Natalia Ipatova, Kihyun Kim, Maria-Theresa Krauth, Irina Kryuchkova, Mihaela Cornelia Lazaroiu, Mario Luppi, Andrei Proydakov, Alessandro Rambaldi, Milda Rudzianskiene, Su-Peng Yeh, Maria Magdalena Alcalá-Peña, Adrian Alegre Amor, Hussain Alizadeh, Maurizio Bendandi, Gillian Brearton, Randall Brown, Jim Cavet, Najib Dally, Miklos Egyed, José Ángel Hernández-Rivas, Ain Kaare, Jean-Michel Karsenti, Janusz Kloczko, William Kreisle, Je-Jung Lee, Sigrid Machherndl-Spandl, Sudhir Manda, Ivan Moiseev, Jan Moreb, Zsolt Nagy, Santosh Nair, Albert Oriol-Rocafiguera, Michael Osswald, Paula Otero-Rodriguez, Valdas Peceliunas, Torben Plesner, Philippe Rey, Giuseppe Rossi, Don Stevens, Celia Suriu, Corrado Tarella, Anke Verlinden, Alain Zannetti
Publikováno v:
The Lancet Haematology, 9(2), e98-e110. Lancet Publishing Group
Digital.CSIC. Repositorio Institucional del CSIC
instname
Digital.CSIC. Repositorio Institucional del CSIC
instname
Background Melphalan flufenamide (melflufen), an alkylating peptide-drug conjugate, plus dexamethasone showed clinical activity and manageable safety in the phase 2 HORIZON study. We aimed to determine whether melflufen plus dexamethasone would provi
Autor:
Hani Hassoun, Jacob P. Laubach, Jan S. Moreb, Sara Thuresson, Paula Rodriguez-Otero, Marcus Thuresson, Michele Cavo, Albert Oriol, Maria-Victoria Mateos, Joan Bladé, John W. Hiemenz, Adrian Alegre, Amitabha Mazumder, Horizon (Op ) Investigators, Kenneth C. Anderson, Omar Nadeem, Johan Harmenberg, Nicolaas A Bakker, Xavier Leleu, Alessandra Larocca, Christopher Maisel, Paul G. Richardson, Agne Paner, Anastasios Raptis, Cyrille Touzeau, Catriona Byrne
Publikováno v:
Journal of Clinical Oncology
Journal of Clinical Oncology, 2021, 39 (7), pp.757-767. ⟨10.1200/JCO.20⟩
Journal of Clinical Oncology, American Society of Clinical Oncology, 2021, 39 (7), pp.757-767. ⟨10.1200/JCO.20⟩
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Journal of Clinical Oncology, 2021, 39 (7), pp.757-767. ⟨10.1200/JCO.20⟩
Journal of Clinical Oncology, American Society of Clinical Oncology, 2021, 39 (7), pp.757-767. ⟨10.1200/JCO.20⟩
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
PURPOSE Melphalan flufenamide (melflufen) is a first-in-class peptide-drug conjugate that targets aminopeptidases and rapidly and selectively releases alkylating agents into tumor cells. The phase II HORIZON trial evaluated the efficacy of melflufen
Autor:
Peter M. Voorhees, Hanan Zubair, Antonio Palumbo, Claudia E. Paba-Prada, Kenneth C. Anderson, Johan Harmenberg, Sara Bringhen, Catriona Byrne, Brandi Reeves, Ulf-Henrik Mellqvist, Torben Plesner, Paul G. Richardson, Eva Nordström, Pieter Sonneveld, Dharminder Chauhan
Publikováno v:
Richardson, P G, Bringhen, S, Voorhees, P, Plesner, T, Mellqvist, U H, Reeves, B, Paba-Prada, C, Zubair, H, Byrne, C, Chauhan, D, Anderson, K, Nordström, E, Harmenberg, J, Palumbo, A & Sonneveld, P 2020, ' Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1) : a multicentre, international, open-label, phase 1–2 study ', The Lancet Haematology, vol. 7, no. 5, pp. e395-e407 . https://doi.org/10.1016/S2352-3026(20)30044-2
Lancet Haematology, 7(5), E395-E407. Lancet Publishing Group
Lancet Haematology, 7(5), E395-E407. Lancet Publishing Group
Summary Background Multiple myeloma is an incurable haematological malignancy, representing over 10% of haematological cancers in the USA. We did a phase 1–2 study of melflufen and dexamethasone in patients with relapsed and refractory multiple mye
Autor:
Pieter Sonneveld, Johan Harmenberg, Sara Bringhen, Paul G. Richardson, Peter M. Voorhees, Catriona Byrne, Brandi Reeves, Ulf-Henrik Mellqvist, Torben Plesner, Eva Nordström, Jakob Obermüller
Publikováno v:
Bringhen, S, Voorhees, P M, Plesner, T, Mellqvist, U-H, Reeves, B, Sonneveld, P, Byrne, C, Nordström, E, Harmenberg, J, Obermüller, J & Richardson, P G 2021, ' Melflufen plus dexamethasone in relapsed/refractory multiple myeloma : long-term survival follow-up from the Phase II study O-12-M1 ', British Journal of Haematology, vol. 193, no. 6, pp. 1105-1109 . https://doi.org/10.1111/bjh.17302
British Journal of Haematology
British Journal of Haematology
Summary An updated survival analysis was conducted for the Phase II study O‐12‐M1 of melphalan flufenamide (melflufen) plus dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM) with two or more prior lines of therapy (includ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70e85b5ff4c125b9690f74ca7c52f85d
https://findresearcher.sdu.dk:8443/ws/files/190556676/Open_Access_Version.pdf
https://findresearcher.sdu.dk:8443/ws/files/190556676/Open_Access_Version.pdf
Autor:
Zhaoyang Teng, Andrew Spencer, Catriona Byrne, Wiesław Wiktor Jędrzejczak, Shaji Kumar, Marie-Christine Kyrtsonis, Norbert Grzasko, Meletios A. Dimopoulos, Richard Labotka, Neeraj Gupta, Sebastian Grosicki, Sosana Delimpasi
Publikováno v:
British Journal of Haematology. 184:536-546
There is a need for efficacious, convenient treatments with long-term tolerability for patients with relapsed/refractory multiple myeloma (RRMM). This phase 2 study evaluated the all-oral combination of ixazomib, cyclophosphamide and dexamethasone (I
Autor:
Noopur Raje, Michaela Liedtke, Jose Estevam, Eileen Liao, Alessandra Di Bacco, Catriona Byrne, Daniel Lebovic, Rachid Baz, Myo Htut, Craig C. Hofmeister, Deborah Berg, Jesus G. Berdeja, Ajai Chari, Cara A. Rosenbaum, David H. Vesole, Paul G. Richardson, Stephen D. Smith, Neeraj Gupta
Publikováno v:
British Journal of Haematology
Summary Weekly ixazomib with lenalidomide‐dexamethasone (Rd) is feasible and has shown activity in newly diagnosed multiple myeloma (NDMM) patients. This phase 1/2 study (NCT01383928) evaluated the recommended phase 2 dose (RP2D), pharmacokinetics,
Autor:
Meletios-Athanasios Dimopoulos, Fredrik Schjesvold, Maria-Victoria Mateos, Johan Harmenberg, Catriona Byrne, Marcus Thuresson, Pawel Robak, Pieter Sonneveld, Paul G. Richardson, Roman Hájek
Publikováno v:
Blood. 138:4779-4779
Background: Most pts with MM will be exposed to alkylators throughout their disease course as part of a multidrug regimen or as high-dose melphalan (HDM) conditioning prior to undergoing an autologous stem cell transplant (SCT). MM invariably relapse
Autor:
Catriona Byrne, Pieter Sonneveld, Daniel Coriu, Paul G. Richardson, Torbjörn Kullenburg, Maria-Victoria Mateos, Marcus Thuresson, Antonio Lazzaro, Johan Harmenberg, Haifaa Abdulhaq, Fredrik Schjesvold
Publikováno v:
Blood. 138:2732-2732
Background: Most pts with MM are older (median age at diagnosis: 69 y), have comorbidities (Engelhardt, et al. Haematologica. 2017;102:910), and often relapse. Thus, there is a high unmet need for novel, tolerable agents to treat RRMM. Melphalan fluf
Autor:
Maria-Victoria Mateos, Pawel J. Robak, Laura Rosiñol, Argiris Symeonidis, Pieter Sonneveld, Marcus Thuresson, Catriona Byrne, Johan Harmenberg, Roman Hájek
Publikováno v:
Blood. 138:2741-2741
Background: Older patients (pts) with relapsed/refractory multiple myeloma (RRMM) represent a particularly difficult-to-treat population due to comorbidities, frailty or reduced fitness level, and treatment with concomitant medications (Larocca et al